Intech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Intech Investment Management LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 25,632 shares of the biopharmaceutical company’s stock, valued at approximately $871,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Novo Holdings A S grew its stake in shares of Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after buying an additional 113,663 shares during the last quarter. Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter. AlphaCentric Advisors LLC grew its position in Celldex Therapeutics by 23.4% during the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock worth $1,758,000 after acquiring an additional 9,000 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after purchasing an additional 654,194 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Celldex Therapeutics by 14.6% in the second quarter. Bank of New York Mellon Corp now owns 230,162 shares of the biopharmaceutical company’s stock valued at $8,518,000 after purchasing an additional 29,324 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CLDX. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Citigroup initiated coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Stock Up 4.2 %

CLDX stock opened at $27.89 on Friday. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -10.85 and a beta of 1.60. The company’s fifty day simple moving average is $29.09 and its 200 day simple moving average is $34.55. Celldex Therapeutics, Inc. has a 12-month low of $22.93 and a 12-month high of $53.18.

Insider Activity

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.80% of the stock is owned by company insiders.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.